Comparison of inhaled heparin/N-acetylcysteine, N-acetylcystein alone, and placepo for the treatment of COVID-19 patients

Comparison of the efficacy of inhaled heparin/N-acetylcysteine, N-acetylcystein alone, and placepo for the treatment of COVID-19 patients admitted to the hospital

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201210049672N1

Enrollment

Registered

2022-03-17

Start date

2022-03-11

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: Protocol treatments + 2 ml heparin from the 5000 IU vial and 3 ml N-acetyl cysteine 20% amounting to a total of nebulized 5 ml solution, every 4 hours, daily for 7

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Definitive COVID-19 diagnosis based on PCR results Admission to the intensive care unit

Exclusion criteria

Exclusion criteria: Hypersensitivity to heparin and N-acetyl cysteine Coagulopathies

Design outcomes

Primary

Measure	Time frame
Intensive care unit length of stay. Timepoint: At the end of the study. Method of measurement: Checklist.	—

Secondary

Measure	Time frame
Tracheal intubation requirement. Timepoint: Any time during the study. Method of measurement: Checklist.;Mechanical ventilation requirement. Timepoint: Any time during the study. Method of measurement: Checklist.;Death. Timepoint: Any time during the study. Method of measurement: Checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBibimona Razavi

Bandare-abbas University of Medical Sciences

bibimonarazavi.hums@gmail.com+98 76 3334 5009

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026